In vitro study of the potential role of quinupristin/dalfopristin in the treatment of catheter-related staphylococcal infections.
The susceptibility of clinical isolates of methicillin-susceptible and -resistant staphylococci from cancer patients with central venous catheter bacteremia to quinupristin/dalfopristin, a semisynthetic streptogramin, was determined in vitro. Susceptibility of these isolates to nine other antistaphylococcal antibiotics was also determined for comparison. A total of 197 staphylococcal strains were tested from 1983 to 1992. Quinupristin/dalfopristin was bactericidal against all isolates, independent of their resistance to methicillin. Its activity was similar to that of vancomycin but superior to that of teicoplanin. Quinupristin/dalfopristin may prove to be an important addition to our armamentarium against catheter-related staphylococcal infections.
Garcia
R
R
University of Texas M.D. Anderson Cancer Center, Department of Medical Specialties, Houston 77030, USA.
Raad
I
I
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology; D000904:Antibiotics, Antitubercular / Q000494:pharmacology; D016470:Bacteremia / Q000150:complications / Q000382:microbiology; D002405:Catheterization, Central Venous / Q000009:adverse effects*; D002435:Cefamandole / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D002939:Ciprofloxacin / Q000494:pharmacology; D002981:Clindamycin / Q000494:pharmacology; D017576:Daptomycin / Q000494:pharmacology; D006801:Humans; D008712:Methicillin / Q000627:therapeutic use; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D009369:Neoplasms / Q000382:microbiology; D009675:Novobiocin / Q000494:pharmacology; D010068:Oxacillin / Q000494:pharmacology; D010406:Penicillins / Q000627:therapeutic use; D012293:Rifampin / Q000494:pharmacology; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D013212:Staphylococcus epidermidis / Q000187:drug effects*; D017334:Teicoplanin / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology; D014769:Virginiamycin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000904:Antibiotics, Antitubercular; D002511:Cephalosporins; D010406:Penicillins; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D009675:Novobiocin; D002981:Clindamycin; D002435:Cefamandole; D002939:Ciprofloxacin; D017334:Teicoplanin; D014640:Vancomycin; D017576:Daptomycin; D008712:Methicillin; D010068:Oxacillin; D012293:Rifampin